» Articles » PMID: 39201479

LC/MS-Based Untargeted Lipidomics Reveals Lipid Signatures of Sarcopenia

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Aug 29
PMID 39201479
Authors
Affiliations
Soon will be listed here.
Abstract

Sarcopenia, a multifactorial systemic disorder, has attracted extensive attention, yet its pathogenesis is not fully understood, partly due to limited research on the relationship between lipid metabolism abnormalities and sarcopenia. Lipidomics offers the possibility to explore this relationship. Our research utilized LC/MS-based nontargeted lipidomics to investigate the lipid profile changes as-sociated with sarcopenia, aiming to enhance understanding of its underlying mechanisms. The study included 40 sarcopenia patients and 40 control subjects matched 1:1 by sex and age. Plasma lipids were detected and quantified, with differential lipids identified through univariate and mul-tivariate statistical analyses. A weighted correlation network analysis (WGCNA) and MetaboAna-lyst were used to identify lipid modules related to the clinical traits of sarcopenia patients and to conduct pathway analysis, respectively. A total of 34 lipid subclasses and 1446 lipid molecules were detected. Orthogonal partial least squares discriminant analysis (OPLS-DA) identified 80 differen-tial lipid molecules, including 38 phospholipids. Network analysis revealed that the brown module (encompassing phosphatidylglycerol (PG) lipids) and the yellow module (containing phosphati-dylcholine (PC), phosphatidylserine (PS), and sphingomyelin (SM) lipids) were closely associated with the clinical traits such as maximum grip strength and skeletal muscle mass (SMI). Pathway analysis highlighted the potential role of the glycerophospholipid metabolic pathway in lipid me-tabolism within the context of sarcopenia. These findings suggest a correlation between sarcopenia and lipid metabolism disturbances, providing valuable insights into the disease's underlying mechanisms and indicating potential avenues for further investigation.

References
1.
Kuronuma K, Mitsuzawa H, Takeda K, Nishitani C, Chan E, Kuroki Y . Anionic pulmonary surfactant phospholipids inhibit inflammatory responses from alveolar macrophages and U937 cells by binding the lipopolysaccharide-interacting proteins CD14 and MD-2. J Biol Chem. 2009; 284(38):25488-500. PMC: 2757950. DOI: 10.1074/jbc.M109.040832. View

2.
Bi B, Dong X, Yan M, Zhao Z, Liu R, Li S . Dyslipidemia is associated with sarcopenia of the elderly: a meta-analysis. BMC Geriatr. 2024; 24(1):181. PMC: 10885450. DOI: 10.1186/s12877-024-04761-4. View

3.
Smith G, Julliand S, Reeds D, Sinacore D, Klein S, Mittendorfer B . Fish oil-derived n-3 PUFA therapy increases muscle mass and function in healthy older adults. Am J Clin Nutr. 2015; 102(1):115-22. PMC: 4480667. DOI: 10.3945/ajcn.114.105833. View

4.
De Spiegeleer A, Beckwee D, Bautmans I, Petrovic M . Pharmacological Interventions to Improve Muscle Mass, Muscle Strength and Physical Performance in Older People: An Umbrella Review of Systematic Reviews and Meta-analyses. Drugs Aging. 2018; 35(8):719-734. DOI: 10.1007/s40266-018-0566-y. View

5.
Wolfgang M . Remodeling glycerophospholipids affects obesity-related insulin signaling in skeletal muscle. J Clin Invest. 2021; 131(8). PMC: 8262494. DOI: 10.1172/JCI148176. View